22.2: Cardiac Emergency Drugs

Pharmacology for Nurses · LibreTexts

0%

Contents

    Text

    Size
    100%
    Theme
    Typeface
    Line length
    Spacing

    Read aloud

    How

    Speed: 1×
    Light up
    Highlight

    Symbols: Mulberry Symbols, © 2018–2026 Steve Lee, CC BY-SA 4.0 (licence, the set), the site's own copies.

    From LibreTexts, under CC BY 4.0, as the source states it; its equations are written in TeX, which the PDF shows typeset. This page at LibreTexts.

    22.2: Cardiac Emergency Drugs
    Learning Objectives

    By the end of this section, you should be able to:

    • 22.2.1 Identify the characteristics of drugs used to treat cardiac emergencies.
    • 22.2.2 Explain the indications, actions, adverse reactions, and interactions of drugs used to treat cardiac emergencies.
    • 22.2.3 Describe nursing implications of drugs used to treat cardiac emergencies.
    • 22.2.4 Explain the client education related to drugs used to treat cardiac emergencies.

    The goal of treatment for a client with AMI or unstable angina is restoring the blood supply to the affected area of the heart muscle. Drugs can help either supply more oxygen to the heart (temporarily) or reduce the heart’s demand for oxygen. If there is stenosis (narrowing) in a coronary artery, the definitive treatment is having the client undergo stent placement or, if stenting is not an option, coronary artery bypass grafting. It is very important that this treatment not be delayed because it can save heart tissue. Thrombolytic therapy may also be used to dissolve an occlusive clot that is causing the coronary ischemia or infarction. Thrombolytic therapy is discussed in Anticoagulant, Antiplatelet, and Thrombolytic Drugs.

    Acute Myocardial Infarction and Unstable Angina Drugs

    Four classifications of drugs may be used in emergency situations for AMI and unstable angina: aspirin, oxygen, nitroglycerin, and, occasionally, morphine. In either AMI or unstable angina, the most important thing to consider is blood supply to the heart. If the cardiac cells are not receiving blood, they will become ischemic and eventually will die. Each of the medications is used to enhance oxygen-rich blood flow to the heart.

    Aspirin

    Salicylic acid (aspirin) has been used for mild pain relief for more than 100 years. (Pain Response Drugs discusses aspirin as a nonopioid analgesic.) It was also found to work as an antiplatelet drug; therefore, it is useful in suspected AMI and unstable angina. Aspirin irreversibly binds to receptors on platelets, which prevents them from sticking to other platelets. Because platelet aggregation is the first step in blood clotting, if this can be reduced, then the heart may receive more blood.

    Adverse Effects and Contraindications

    Aspirin can cause gastritis and bleeding in the stomach, other parts of the gastrointestinal tract, brain, and spinal cord.

    Contraindications to aspirin are allergy to nonsteroidal anti-inflammatory drugs (NSAIDs), asthma, hemophilia, and other blood clotting disorders. Pediatric clients who have suspected viral illnesses should not take aspirin because Reye’s syndrome, a potentially fatal complication, could develop. As a precaution, aspirin is generally not used in pediatric clients.

    Table 22.1 is a drug prototype table for aspirin used in emergency situations. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.

    Drug Class
    Salicylic acid

    Mechanism of Action
    Irreversibly binds with receptors on platelets, which makes them unable to bind with other platelets
    Drug Dosage
    For acute myocardial infarction or unstable angina: 325 mg orally (chewed) once. (If client is unable to take orally, administer rectal suppository form.)
    Indications
    Mild pain
    Platelet inhibition in suspected AMI or unstable angina

    Therapeutic Effects
    Platelet inhibition
    Relief of mild pain
    Drug Interactions
    Anticoagulants

    Food Interactions
    Alcohol
    Tobacco
    Adverse Effects
    Gastrointestinal upset/gastritis
    Gastrointestinal bleeding
    Contraindications
    Allergy to NSAIDs
    Asthma
    Hemophilia
    Pediatric clients (risk of developing Reye’s syndrome)
    Table 22.1 Drug Prototype Table: Aspirin (source: https://dailymed.nlm.nih.gov/dailymed/)

    Nursing Implications

    The nurse should do the following for clients who are taking aspirin:

    • Assess the client’s allergies and verify that they are not allergic to any of the NSAIDs.
    • Assess for signs and symptoms of bleeding.
    • In the event of suspected AMI or unstable angina, direct the client to chew the aspirin and then swallow it.
    • Provide client teaching regarding the drug. See below for client teaching guidelines.

    Client Teaching Guidelines

    The client taking aspirin in an emergency situation should:

    • Inform the health care team if they have an allergy to aspirin or other NSAIDs or have a diagnosis of asthma.
    • Chew the aspirin tablet before swallowing.

    See Anticoagulant, Antiplatelet, and Thrombolytic Drugs for full client teaching guidelines on the use of aspirin in nonemergency situations.

    FDA Black Box Warning

    Aspirin

    The risk of serious bleeding in the stomach, gastrointestinal tract, brain, and spinal cord is increased with aspirin and other NSAIDs.

    Concomitant use of aspirin greater than 100 mg per day can reduce the efficacy of ticagrelor (an antiplatelet medication) and should be avoided.

    Oxygen

    In an AMI or unstable angina, the cardiac cells are deprived of oxygen. When cells are deprived of oxygen, they eventually will die. Supplemental oxygen may be used if the client’s oxygen saturation is less than 94% on room air. In the past, oxygen was used immediately for clients with suspected AMI or unstable angina; however, it was not found to be beneficial if used in clients who were already maintaining an oxygen saturation of 95% or more (Hofmann et al., 2017). Oxygen is typically delivered via nasal cannula starting at 2 L/min and can be titrated to 6 L/min. If the client requires a higher dose to maintain oxygen saturation greater than 94%, then other methods of oxygen delivery should be used.

    Nitroglycerin

    Nitroglycerin is a nitrate and a first-line treatment for clients with AMI or unstable angina. Nitroglycerin is converted to nitrous oxide, which ultimately causes smooth muscles around arteries to relax. Smooth muscle relaxation causes vasodilation. In AMI or unstable angina, the cardiac myocytes are not receiving enough oxygen, and vasodilation allows more oxygen to be delivered to hypoxic cells. In emergency situations, nitroglycerin is administered either sublingually or intravenously.

    Antihypertensive and Antianginal Drugs discusses nitrates more extensively.

    Adverse Effects and Contraindications

    Adverse effects include orthostatic hypotension, tachycardia, paradoxical bradycardia, flushing, peripheral edema, nausea and vomiting, headache, and blurred vision.

    Contraindications include allergies to nitrates, concomitant use of phosphodiesterase (PDE) inhibitors such as tadalafil and sildenafil, history of right ventricular infarction, and hypertrophic cardiomyopathy.

    Nitrates should be used cautiously in clients who are on chronic diuretic therapy, have low systolic blood pressure, have autonomic nervous system dysregulation, or are pregnant or breastfeeding.

    Safety Alert

    Nitroglycerin

    Nitrates can cause hypotension. In an emergency situation, make sure the client is sitting or lying down before administering nitroglycerin.

    Table 22.2 is a drug prototype table for nitroglycerin use in emergency situations. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.

    Drug Class
    Nitrate

    Mechanism of Action
    Converts to nitric oxide, which ultimately causes smooth muscle relaxation and vasodilation
    Drug Dosage
    For acute myocardial infarction or unstable angina:
    Sublingual: 0.15–0.6 mg as needed for chest pain every 5 min up to 3 times.
    Intravenous (IV): 5–10 mcg/min up to 100 mcg/min.
    Indications
    For acute relief of pain in suspected acute myocardial infarction or unstable angina

    Therapeutic Effects
    Relieves pain
    Increases delivery of oxygen to cardiac tissue
    Drug Interactions
    Avanafil
    Riociguat
    Sildenafil
    Tadalafil
    Vardenafil

    Food Interactions
    Alcohol
    Tobacco
    Adverse Effects
    Orthostatic hypotension
    Tachycardia
    Paradoxical bradycardia
    Flushing
    Peripheral edema
    Nausea and vomiting
    Headache
    Blurred vision
    Contraindications
    Allergy to nitrates
    Hypersensitivity
    Increased intracranial pressure
    Cardiomyopathy
    History of right ventricular infarction
    Shock

    Caution:
    Chronic diuretic therapy
    Low systolic blood pressure
    Autonomic system dysregulation
    Pregnancy
    Lactation
    Table 22.2 Drug Prototype Table: Nitroglycerin (source: https://dailymed.nlm.nih.gov/dailymed/)

    Nursing Implications

    Refer to Antihypertensive and Antianginal Drugs for a full list of nursing implications for clients prescribed nitrates. In the event of suspected AMI or unstable angina, the health care provider may order sublingual nitroglycerin until an IV line is in place. If the client is receiving IV nitroglycerin, the nurse will receive orders to titrate the nitroglycerin based on pain level and blood pressure.

    The nurse should do the following for clients who are receiving nitroglycerin intravenously for chest pain:

    • Place the client on continuous cardiac monitoring.
    • Monitor vital signs frequently, particularly blood pressure, because nitroglycerin can cause significant hypotension.
    • If symptomatic hypotension occurs, do not give the nitroglycerin and inform the health care provider.
    • Frequently assess pain level.
    • Assess for headache and give pain medication for it as ordered.
    • Provide client teaching regarding the drug. See below for client teaching guidelines.

    Client Teaching Guidelines

    The client receiving nitroglycerin for unstable angina or AMI should:

    • Alert the nurse if any of these occur:
      • Their chest pain changes (either improves or worsens)
      • They feel faint
      • They experience nausea or vomiting

    See Antihypertensive and Antianginal Drugs for full client teaching guidelines on nitroglycerin, including client home usage.

    Morphine

    Morphine is a potent, fast-acting opioid agonist. It binds to opioid receptors in the central and peripheral nervous systems to modulate (decrease) the pain response. Morphine also can help relieve anxiety, which may lower heart rate and reduce the heart’s demand for oxygen. For many years, morphine was a first-line drug in the emergency management of AMI and unstable angina, but now it is used if nitroglycerin cannot control the chest pain (Hermiz & Sedhai, 2023). Pain Response Drugs covers opioid agonists in depth.

    Adverse Effects and Contraindications

    Opioids must be managed carefully due to their potential adverse effects, which include respiratory depression, respiratory arrest, apnea, circulatory depression, shock, cardiac arrest, sedation, lightheadedness, dizziness, nausea, vomiting, and constipation.

    Opioids should not be used if the client has a known hypersensitivity to morphine, respiratory depression, acute or severe asthma, hypercarbia, or a paralytic ileus.

    Safety Alert

    Opioid Analgesics

    Morphine can cause respiratory depression, respiratory arrest, cardiac arrest, and shock. Nurses must monitor the client frequently (reassess at least every 5–10 minutes) when using morphine to control pain.

    Table 22.3 is a drug prototype table for opioid agonists featuring morphine. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.

    Drug Class
    Opioid agonist

    Mechanism of Action
    Primarily a mu opioid receptor agonist that causes modulation of pain in the central and peripheral nervous systems
    Drug Dosage
    For acute myocardial infarction if optimal nitroglycerin does not control chest pain: 4–8 mg IV initially, then 2–8 mg IV repeated every 5–15 minutes if needed for complete pain relief.
    Indications
    For management of pain not responsive to nonnarcotic analgesics

    Therapeutic Effects
    Relieves pain
    Drug Interactions
    Central nervous system depressants:
    • Other narcotic analgesics
    • Phenothiazines
    • Tricyclic antidepressants
    • Tranquilizers
    • Sedatives
    • Hypnotics
    • Antiemetics
    Muscle relaxants
    Cimetidine
    Anticholinergics

    Food Interactions
    Alcohol
    Adverse Effects
    Respiratory depression
    Respiratory arrest
    Apnea
    Circulatory depression
    Shock
    Cardiac arrest
    Sedation
    Lightheadedness
    Dizziness
    Nausea
    Vomiting
    Constipation
    Contraindications
    Known hypersensitivity to morphine
    Respiratory depression
    Acute or severe bronchial asthma or hypercarbia
    Paralytic ileus
    Table 22.3 Drug Prototype Table: Morphine (source: https://dailymed.nlm.nih.gov/dailymed/)

    Nursing Implications

    The nurse should do the following for clients who are receiving morphine for chest pain:

    • Place the client on continuous cardiac monitoring.
    • Assess the client’s vital signs and level of consciousness before administering morphine intravenously.
    • Reassess vital signs and level of consciousness frequently after administering morphine intravenously.
    • If the client’s respiratory rate is less than 10 breaths/min, inform the health care provider.
    • Assess the client’s pain frequently.
    • Reassess the client’s pain 15 minutes after administering morphine.
    • Ensure that a morphine reversal agent (naloxone) is available.
    • Provide client teaching regarding the drug. See below for client teaching guidelines.

    Client Teaching Guidelines

    The client receiving morphine for unstable angina or AMI should:

    • Alert the nurse if any of these occur:
      • Their chest pain changes (either improves or worsens)
      • They feel sleepy, dizzy, or lightheaded
      • They experience nausea or vomiting

    See Pain Response Drugs for full client teaching guidelines on morphine.

    FDA Black Box Warning

    Morphine

    Life-threatening respiratory depression, addiction, abuse, and misuse can occur with morphine use. Concomitant use of morphine with benzodiazepines or other central nervous system depressants may result in profound sedation and/or respiratory depression.

    Dysrhythmia Drugs

    There is a saying in cardiac nursing that there are only three problems with the conduction system: The heart can beat too fast, too slow, or not at all.

    This is an oversimplification, but each one of these problems can lead to hemodynamic instability and potentially death. Once again, the importance of cardiac output cannot be emphasized enough. Cardiac output is a function of heart rate and stroke volume. If the heart rate is too fast, then ventricular filling cannot occur, and cardiac output is affected. If the heart rate is too slow, then not enough blood will be pumped, and cardiac output is affected. If there is no heart rate at all, then, of course, there is no cardiac output.

    The cardiac conduction system—specifically, the SA node—determines the heart rate. The SA node is influenced by the sympathetic and parasympathetic nervous systems. As with all other tissues in the body, it must have a blood supply, and it needs the correct amount of electrolytes (sodium, potassium, calcium, and chloride) to function optimally. The cardiac conduction system (see Figure 22.4) includes the SA node, the AV node, the bundle of His, and the Purkinje fibers.

    Although the main pacemaker of the heart is the SA node, other areas of the conduction system generate electrical impulses. The SA node generates impulses at 60–100 beats/min, the AV node at 40–60 beats/min, and the ventricles at 20–40 beats/min. Typically, the conduction system will conduct the fastest rate, which is why the system normally follows the SA node impulses.

    Cardiac conduction can be categorized by area of the heart: atrial conduction and ventricular conduction. Most conduction problems in the atria are not life-threatening, but supraventricular tachycardia, atrial fibrillation with rapid ventricular response, and sick sinus syndrome (which can cause hemodynamically unstable bradycardia) can cause hemodynamic instability and potentially death. Ventricular dysrhythmias nearly always cause hemodynamic instability and will lead to death if not treated rapidly. Ventricular dysrhythmias include ventricular tachycardia, pulseless ventricular tachycardia, and ventricular fibrillation.

    Emergency dysrhythmias discussed in this chapter include:

    • Asystole: Complete cessation of electrical activity in the heart
    • Atrial fibrillation with rapid ventricular response: Rapid electrical stimulation and conduction that cause the atria to have unorganized contraction (fibrillation) and the ventricles to beat rapidly
    • Symptomatic bradycardia: Heart rate less than 60 beats per minute that negatively affects cardiac output
    • Pulseless electrical activity: Life-threatening dysrhythmia in which the electrical system conducts impulses but the cardiac myocytes do not respond
    • Pulseless ventricular tachycardia: Life-threatening dysrhythmia in which the ventricles contract so rapidly that a pulse cannot be detected
    • Supraventricular tachycardia: Rapid heart rate that originates from above the ventricles
    • Ventricular fibrillation: Life-threatening dysrhythmia originating in the ventricles in which ventricles are not coordinated in their contraction, leading to minimal cardiac output
    • Ventricular tachycardia: Dysrhythmia that originates from the ventricles and causes them to contract rapidly; if it becomes fast enough, it can turn into pulseless ventricular tachycardia, which is life-threatening

    The drugs described in this section are used in emergency situations to restore hemodynamic stability and improve cardiac conduction. Antiarrhythmic drugs that are used long term are discussed in Antidysrhythmic Drugs.

    Adenosine

    Adenosine is a class V antidysrhythmic drug. It is used to convert supraventricular tachycardia into normal sinus rhythm (the regular conduction pattern of the heart). Adenosine affects how potassium and calcium move into and out of the myocardial conduction cells that affect the resting membrane potential, causing conduction to take longer. This is useful in disrupting supraventricular tachycardia and gives the heart the opportunity to restart in normal sinus rhythm.

    Adverse Effects and Contraindications

    Adenosine may cause flushing of the skin, palpitations, chest pain, hypotension, lightheadedness, nausea, sweating, nervousness, numbness, and apprehension. It decreases conduction through the AV node and may produce short-lasting heart block. It is important to note that the benefit of adenosine in a life-threatening event outweighs the risk of adverse effects.

    Contraindications to adenosine include second- or third-degree heart block (except in clients with a pacemaker), sinus node disease (sick sinus syndrome or symptomatic bradycardia), and known hypersensitivity to adenosine.

    Table 22.4 is a drug prototype table for adenosine use in emergency situations. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.

    Drug Class
    Class V antiarrhythmic

    Mechanism of Action
    Affects potassium and calcium channels in the myocardial conducting cells, significantly slowing heart rate
    Drug Dosage
    For supraventricular tachycardia: 6 mg rapid IV bolus (administered over 1–2 seconds); if supraventricular tachycardia is not eliminated, administer 12 mg rapid IV bolus. The 12 mg dose may be repeated once if required.
    Indications
    To convert supraventricular tachycardia to normal sinus rhythm

    Therapeutic Effects
    Slows nerve impulses in the heart
    Drug Interactions
    Methylxanthines (caffeine, theophylline)
    Dipyridamole
    Carbamazepine

    Food Interactions
    Caffeine
    Adverse Effects
    Flushing of skin
    Palpitations
    Chest pain
    Hypotension
    Lightheadedness
    Nausea
    Sweating
    Nervousness
    Numbness
    Apprehension
    Short-lasting heart block due to decreased conduction through the AV node
    Contraindications
    Second- or third-degree heart block (except in clients with a pacemaker)
    Sinus node disease (sick sinus syndrome or symptomatic bradycardia)
    Known hypersensitivity to adenosine
    Table 22.4 Drug Prototype Table: Adenosine (sources: https://dailymed.nlm.nih.gov/dailymed/; Singh & McKintosh, 2022)

    Clinical Tip

    Adenosine

    Adenosine has a very short half-life and should be administered as a rapid IV bolus directly into a vein, followed by a rapid saline flush.

    Nursing Implications

    The nurse should do the following for clients who are receiving adenosine intravenously:

    • Place the client on continuous cardiac monitoring.
    • Monitor vital signs frequently.
    • Administer adenosine as an IV push directly into a vein over 1–2 seconds.
    • Administer a rapid saline bolus immediately after administering adenosine.
    • Be prepared to administer a second dose.
    • If the client is alert, inform them that they may feel chest pain once the bolus is given. The chest pain should subside quickly (in less than 1 minute).
    • Provide client teaching regarding the drug. See below for client teaching guidelines.

    Client Teaching Guidelines

    In supraventricular tachycardia, the client may not be conscious because of decreased cardiac output.

    If alert and oriented, the client receiving adenosine should:

    • Inform the health care team if they have a known heart block or sick sinus syndrome.

    Amiodarone

    Amiodarone is a class III antiarrhythmic drug used for hemodynamically unstable ventricular tachycardia, ventricular fibrillation, and other dysrhythmias. It blocks potassium and calcium channels from opening, which slows down cardiac conduction and therefore slows heart rate. Antidysrhythmic Drugs covers the use of amiodarone in the management of chronic dysrhythmias.

    Adverse Effects and Contraindications

    Amiodarone can cause hypotension, bradycardia, atrioventricular block, hepatic injury, heart rhythm disturbances, pulmonary injury, loss of vision, thyroid injury, hypersensitivity, anorexia, nausea, vomiting, and photosensitivity. It is important to note that the benefit of amiodarone in a life-threatening event outweighs the risk of adverse effects.

    Contraindications to amiodarone include known hypersensitivity, cardiogenic shock, marked sinus bradycardia, and second- or third-degree AV block (unless the client has an implanted pacemaker).

    Table 22.5 is a drug prototype table for amiodarone use in emergency situations. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.

    Drug Class
    Class III antiarrhythmic

    Mechanism of Action
    Blocks potassium and calcium channels in the cardiac conducting cells, slowing the heart rate
    Drug Dosage
    For hemodynamically unstable ventricular tachycardia or ventricular fibrillation: 150 mg IV bolus given over 10 minutes, then 360 mg IV infused over the next 6 hours, then 540 mg IV infused over the next 18 hours; dosage should be titrated after 24 hours.
    Indications
    For ventricular fibrillation and hemodynamically unstable ventricular tachycardia

    Therapeutic Effects
    Slows nerve impulses in the heart
    Drug Interactions
    Drugs that prolong the QT interval (increased risk of torsade de pointes):
    • Class I antiarrhythmics
    • Class III antiarrhythmics
    • Lithium
    • Phenothiazines
    • Tricyclic antidepressants
    Digoxin (increases effect)
    Warfarin (increases effect)
    HMG-CoA reductase inhibitors/statin drugs (increases effect; risk of myopathy)
    Protease inhibitors
    St. John’s wort

    Food Interactions
    Grapefruit/grapefruit juice
    Adverse Effects
    Anorexia
    Nausea and vomiting
    Hypotension
    Bradycardia and atrioventricular block
    Hepatic injury
    Dysrhythmias
    Photosensitivity
    Pulmonary injury
    Loss of vision
    Thyroid injury
    Hypersensitivity
    Contraindications
    Known hypersensitivity
    Cardiogenic shock
    Marked sinus bradycardia
    Second- or third-degree AV block (unless the client has an implanted pacemaker)
    Table 22.5 Drug Prototype Table: Amiodarone (sources: https://dailymed.nlm.nih.gov/dailymed/; Florek & Girsadas, 2022)

    Safety Alert

    Amiodarone

    Amiodarone can cause pulmonary toxicity and swelling in the lungs.

    Nursing Implications

    The nurse should do the following for clients who are receiving amiodarone intravenously:

    • Place the client on continuous cardiac monitoring.
    • Monitor vital signs frequently.
    • Monitor level of consciousness.
    • Monitor laboratory values and report abnormal findings to the health care provider.
    • Have resuscitative equipment and drugs immediately available.
    • Monitor for adverse effects of amiodarone infusion.
    • Provide client teaching regarding the drug. See below for client teaching guidelines.

    Client Teaching Guidelines

    The client receiving amiodarone should:

    • Inform the health care provider of nausea, which may be an early indication of liver damage.

    Clients with ventricular fibrillation or hemodynamically unstable ventricular tachycardia are typically no longer conscious. See Antidysrhythmic Drugs for client teaching guidelines for amiodarone in less acute situations.

    FDA Black Box Warning

    Amiodarone

    Amiodarone can cause pulmonary toxicity and swelling in the lungs.

    Atropine

    Atropine is a first-line drug used for treating symptomatic bradycardia. It is an anticholinergic drug, which means it blocks receptors in the parasympathetic nervous system. The heart is constantly stimulated by both the parasympathetic nervous system (PNS) and the sympathetic nervous system (SNS). It reacts to whichever system is sending more impulses. If the PNS signals are blocked, then the heart receives fewer signals from acetylcholine, the primary neurotransmitter of the PNS. Because of fewer signals from the PNS, the SNS signaling is stronger, which increases the heart rate.

    Adverse Effects and Contraindications

    Atropine can cause tachycardia, acute glaucoma, pyloric obstruction, and complete urinary retention. It is important to note that the benefit of atropine in a life-threatening event outweighs the risk of adverse effects.

    There are no contraindications to the use of atropine.

    Table 22.6 is a drug prototype table for atropine use in emergency situations. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.

    Drug Class
    Anticholinergic

    Mechanism of Action
    Inhibits cholinergic nerves, resulting in decreased parasympathetic stimulation
    Drug Dosage
    For symptomatic bradycardia: 1 mg IV every 3–5 minutes; maximum dose: 3 mg.
    Indications
    Symptomatic bradycardia
    Treatment of organophosphorus poisoning

    Therapeutic Effects
    Increased heart rate
    Drug Interactions
    Mexiletine

    Food Interactions
    No significant interactions
    Adverse Effects
    Tachycardia
    Acute glaucoma
    Pyloric obstruction
    Complete urinary retention
    Contraindications
    None
    Table 22.6 Drug Prototype Table: Atropine (sources: https://dailymed.nlm.nih.gov/dailymed/; McLendon & Preuss, 2022)

    Nursing Implications

    The nurse should do the following for clients receiving atropine intravenously:

    • Place the client on continuous cardiac monitoring.
    • Monitor vital signs frequently.
    • Monitor level of consciousness.
    • Have resuscitative equipment and drugs available.
    • Provide client teaching regarding the drug. See below for client teaching guidelines.

    Client Teaching Guidelines

    In symptomatic bradycardia, the client may not be conscious because of decreased cardiac output.

    If alert and oriented, the client receiving atropine should:

    • Inform the health care team if they feel different (better or worse) after the initial dose.
    • Inform the health care team if they feel a fast heart rate or racing heart after the dose.

    Diltiazem

    Diltiazem is a nondihydropyridine Calcium channel blocker and a class IV antiarrhythmic drug. Nondihydropyridine calcium channel blockers inhibit calcium flow into cardiac myocytes, which results in decreased force of contractions and decreased heart rate. Therefore, diltiazem is useful for treating supraventricular tachycardia and atrial fibrillation with rapid ventricular response. In addition, calcium channel blockers cause vasodilation and can reduce blood pressure. Antihypertensive and Antianginal Drugs discusses the use of calcium channel blockers in hypertension.

    Adverse Effects and Contraindications

    Diltiazem can cause asystole; atrial flutter; first-, second-, and third-degree atrioventricular block; bradycardia; chest pain; congestive heart failure; sinus pause; sinus node dysfunction; syncope; ventricular dysrhythmia; ventricular fibrillation; ventricular tachycardia; dizziness; allergic reaction; Stevens–Johnson syndrome; and angioedema. It is important to note that the benefit of diltiazem in a life-threatening event outweighs the risk of adverse effects.

    Contraindications include sick sinus syndrome, unless the client has a pacemaker; second- or third-degree heart block, unless the client has a pacemaker; severe hypotension and/or cardiogenic shock; hypersensitivity; ventricular tachycardia; and AMI.

    Diltiazem should not be administered concurrently with IV beta-adrenergic blockers.

    Table 22.7 is a drug prototype table for diltiazem use in emergency situations. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.

    Drug Class
    Nondihydropyridine calcium channel blocker; class IV antiarrhythmic drug

    Mechanism of Action
    Inhibits calcium ions from entering the cell, resulting in decreased force of cardiac contraction and vascular smooth muscle relaxation
    Drug Dosage
    For paroxysmal supraventricular tachycardia or atrial fibrillation with rapid ventricular response: 0.25 mg/kg actual body weight IV bolus over 2 minutes. If response inadequate, 0.35 mg/kg actual body weight IV bolus administered over 2 minutes. Subsequent bolus doses may be administered as needed according to the health care provider’s discretion.

    After initial bolus(es), continuous IV infusion may be needed, starting at 10 mg/hour for up to 24 hours.
    Indications
    Atrial fibrillation with rapid ventricular response
    Supraventricular tachycardia

    Therapeutic Effects
    Slows heart rate
    Lowers blood pressure
    Drug Interactions
    Beta-adrenergic blockers may increase incidence of bradycardia

    Food Interactions
    Alcohol
    Adverse Effects
    Allergic reaction
    Angioedema
    Asystole
    Atrial flutter
    First-degree atrioventricular block
    Second-degree atrioventricular block
    Third-degree atrioventricular block
    Bradycardia
    Chest pain
    Congestive heart failure
    Hypotension
    Sinus pause
    Sinus node dysfunction
    Syncope
    Ventricular dysrhythmia
    Ventricular fibrillation
    Ventricular tachycardia
    Dizziness
    Stevens–Johnson syndrome
    Contraindications
    Sick sinus syndrome (unless client has pacemaker)
    Second- or third-degree heart block (unless client has pacemaker)
    Severe hypotension and/or cardiogenic shock
    Hypersensitivity
    Ventricular tachycardia
    Acute myocardial infarction
    Table 22.7 Drug Prototype Table: Diltiazem (sources: https://dailymed.nlm.nih.gov/dailymed/; Talreja & Cassagnol, 2022)

    Nursing Implications

    The nurse should do the following for clients receiving diltiazem intravenously:

    • Place the client on continuous cardiac monitoring.
    • Monitor blood pressure frequently.
    • Monitor level of consciousness.
    • Have resuscitative equipment and drugs available.
    • Provide client teaching regarding the drug. See below for client teaching guidelines.

    Client Teaching Guidelines

    In supraventricular tachycardia or atrial fibrillation with rapid ventricular response, the client may not be conscious because of decreased cardiac output.

    If alert and oriented, the client receiving diltiazem should:

    • Inform the health care team if they have a known heart block or sick sinus syndrome.

    See Antidysrhythmic Drugs for client teaching guidelines for diltiazem in less acute situations.

    Epinephrine

    Epinephrine (adrenaline) is a hormone that stimulates the SNS during the fight-or-flight response. SNS stimulation results in a faster heart rate, increased cardiac output, and pulmonary dilation (for increased oxygen intake), among other things. Epinephrine is a nonselective adrenergic agonist, which means it stimulates all receptors in the SNS. Epinephrine is used in a variety of emergency situations. In cardiac emergencies, epinephrine is used in ventricular fibrillation, pulseless ventricular tachycardia, asystole, and pulseless electrical activity.

    Adverse Effects and Contraindications

    Epinephrine can cause anxiety and excitability, headache, fear, heart palpitations, tachycardia, supraventricular tachycardia, ventricular arrhythmias, hypertension, cerebral hemorrhage, hemiplegia, subarachnoid hemorrhage, anginal pain in clients with angina, pulmonary edema, hypoglycemia, hypokalemia, and lactic acidosis. It is important to note that the benefit of epinephrine in a life-threatening event outweighs the risk of adverse effects.

    Contraindications to epinephrine include cardiac dilation, coronary artery insufficiency, and shock during general anesthesia. Epinephrine contains sodium bisulfate, which may cause an allergic reaction.

    Table 22.8 is a drug prototype table for epinephrine use in emergency situations. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.

    Drug Class
    Adrenergic agonist (nonselective)

    Mechanism of Action
    Binds to sympathetic nervous system receptors and stimulates the sympathetic nervous system, which causes increased heart rate, increased blood pressure, and increased oxygen intake in the lungs
    Drug Dosage
    For ventricular fibrillation, pulseless ventricular tachycardia, asystole, and pulseless electrical activity: 0.1–1 mg IV bolus (using 0.1 mg/mL concentration) repeated every 5 minutes as necessary during cardiac resuscitation.
    For anaphylaxis: 0.3–0.5 mg intramuscularly (using 1 mg/mL concentration), repeated every 5–10 minutes as needed.
    Indications
    Emergency treatment of type I hypersensitivity reactions (anaphylaxis), ventricular fibrillation, pulseless ventricular tachycardia, asystole, and pulseless electrical activity
    Emergency treatment of anaphylaxis

    Therapeutic Effects
    Increases heart rate
    Increases blood pressure
    Bronchodilation
    Drug Interactions
    Other sympathomimetic (adrenergic stimulant) drugs such as isoproterenol
    Digoxin
    Other medications may potentiate the effects:
    • Tricyclic antidepressants
    • Antihistamines
    • Sodium l-thyroxine
    • Beta-adrenergic blockers
    Rapidly acting nitrates or alpha-blocking agents (may counteract epinephrine’s effects)
    Use with caution in clients taking monoamine oxidase inhibitors

    Food Interactions
    No significant interactions
    Adverse Effects
    Anxiety
    Excitability
    Headache
    Fear
    Heart palpitations
    Tachycardia
    Supraventricular tachycardia
    Ventricular arrhythmias
    Myocardial ischemia
    Hypertension
    Cerebral hemorrhage
    Hemiplegia
    Subarachnoid hemorrhage
    Anginal pain in clients with angina
    Pulmonary edema
    Hypoglycemia
    Hypokalemia
    Lactic acidosis
    Contraindications
    Cardiac dilation
    Coronary artery insufficiency
    Shock during general anesthesia
    Table 22.8 Drug Prototype Table: Epinephrine (sources: https://dailymed.nlm.nih.gov/dailymed/; Dalal & Grujic, 2022; McLendon & Sternard, 2022; Smith & Maani, 2022)

    Nursing Implications

    The nurse should do the following for clients receiving epinephrine intravenously:

    • Place the client on continuous cardiac monitoring.
    • Monitor blood pressure frequently. (Often, blood pressure is measured continuously when client is in shock.)
    • Monitor level of consciousness.
    • Have resuscitative equipment and drugs available.
    • Provide client teaching regarding the drug. See below for client teaching guidelines.

    Client Teaching Guidelines

    In ventricular fibrillation, pulseless ventricular tachycardia, asystole, or pulseless electrical activity, the client will be unconscious. In anaphylaxis, the client may be unconscious.

    If alert and oriented, the client receiving epinephrine should:

    • Inform the health care team if they have a change in status (better or worse) after medication administration.
    • Inform the health care team if they notice a change in their breathing.

    Lidocaine

    Lidocaine is classified as a local anesthetic agent, but it is also a class Ib antiarrhythmic drug used in acute ventricular dysrhythmias. Lidocaine blocks sodium channels, which slows the cardiac action potential and causes the electrical stimulation threshold to be higher. The higher stimulation threshold causes the cardiac conduction cells to be less likely to conduct action potentials, which ultimately treats ventricular tachyarrhythmias.

    Adverse Effects and Contraindications

    Lidocaine can cause respiratory depression and arrest, unconsciousness, convulsions, tremors, twitching, vomiting, blurred or double vision, drowsiness, dizziness, light-headedness, agitation, confusion, paresthesia, and dysarthria. It is important to note that the benefit of lidocaine in a life-threatening event outweighs the risk of adverse effects.

    Contraindications to lidocaine include a history of hypersensitivity, Stokes–Adams syndrome, Wolff–Parkinson–White syndrome, and heart block.

    Table 22.9 is a drug prototype table for lidocaine use in emergency situations. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications. Lidocaine as a topical anesthetic is not addressed in this section.

    Drug Class
    Class Ib antiarrhythmic

    Mechanism of Action
    Blocks sodium channels in cardiac conducting cells, which ultimately causes slowed conduction and decreased heart rate
    Drug Dosage
    For ventricular arrhythmias: 1–1.5 mg/kg IV bolus at 25–50 mg/min. Continuous IV infusion may be needed; usual dosing is 1–4 mg/min.
    Indications
    Emergency management of ventricular arrhythmias

    Therapeutic Effects
    Decreases heart rate
    Drug Interactions
    Other antiarrhythmic drugs (cardiac effects may be additive or antagonistic, which may lead to toxic effects)
    Propranolol, metoprolol, nadolol (increase the serum concentration of lidocaine)

    Food Interactions
    No significant interactions
    Adverse Effects
    Respiratory depression
    Respiratory arrest
    Unconsciousness
    Convulsions
    Tremors
    Twitching
    Vomiting
    Blurred or double vision
    Drowsiness
    Dizziness
    Light-headedness
    Agitation
    Confusion
    Cardiovascular arrest
    Bradycardia, which may lead to cardiovascular arrest
    Hypotension
    Ventricular fibrillation
    Ventricular tachycardia
    Asystole
    Allergic reaction, including anaphylaxis
    Contraindications
    History of known reaction
    Stokes–Adams syndrome
    Wolff–Parkinson–White syndrome
    Severe sinoatrial heart block
    Severe atrioventricular heart block
    Severe intraventricular heart block
    Table 22.9 Drug Prototype Table: Lidocaine (sources: https://dailymed.nlm.nih.gov/dailymed/; Al-Khatib et al., 2018; Beecham et al., 2022; Klabunde, 2022)

    Nursing Implications

    The nurse should do the following for clients receiving lidocaine intravenously:

    • Place the client on continuous cardiac monitoring.
    • Monitor blood pressure frequently.
    • Monitor level of consciousness.
    • Have resuscitative equipment and drugs available.
    • For continuous IV lidocaine infusion, closely monitor the rate and provide continuous ECG monitoring.
    • Monitor for adverse effects of lidocaine infusion
    • Provide client teaching regarding the drug. See below for client teaching guidelines.

    Client Teaching Guidelines

    The client receiving lidocaine should:

    • Inform the health care provider of tremors, twitching, nausea, vomiting, blurred or double vision, dizziness, lightheadedness, or confusion.

    In acute ventricular arrhythmias, clients are typically no longer conscious. See Antidysrhythmic Drugs for client teaching guidelines for lidocaine in less acute situations.

    Procainamide

    Procainamide is a class Ia antiarrhythmic drug that binds to sodium channels, reducing the speed of conduction. It is used in life-threatening ventricular arrhythmias.

    Adverse Effects and Contraindications

    Procainamide can cause hypotension, asystole, ventricular fibrillation, lupus erythematosus–like syndrome, pleural effusions, pericarditis, neutropenia, thrombocytopenia, hemolytic anemia, agranulocytosis, dizziness, weakness, and elevated liver enzyme levels.

    Prolonged use of procainamide often leads to a positive antinuclear antibody (ANA) test; if this occurs, the risk–benefit ratio of procainamide use should be reassessed. It is important to note that the benefit of procainamide in a life-threatening event generally outweighs the risk of adverse effects.

    Contraindications to the use of procainamide include a history of hypersensitivity, complete heart block, atrial fibrillation or flutter, congestive heart failure, lupus erythematosus, torsade de pointes, myasthenia gravis, and sulfite sensitivity.

    Table 22.10 is a drug prototype table for procainamide use in emergency situations. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.

    Drug Class
    Class Ia antiarrhythmic

    Mechanism of Action
    Antagonizes cardiac cell sodium channels, which ultimately slows the heart rate
    Drug Dosage
    For life-threatening ventricular arrhythmias: Loading dose 10–17 mg/kg at a rate of 20–50 mg/min. Maintenance therapy may be indicated; dosing is variable.
    Indications
    Emergency management of ventricular arrhythmias

    Therapeutic Effects
    Decreases heart rate
    Drug Interactions
    Digitalis derivatives
    Other class Ia antiarrhythmic drugs
    Other antiarrhythmic drugs (may prolong the QT interval)

    Food Interactions
    No significant interactions
    Adverse Effects
    Hypotension
    Asystole
    Ventricular fibrillation
    Lupus erythematosus–like syndrome
    Pleural effusion
    Pericarditis
    Neutropenia
    Thrombocytopenia
    Hemolytic anemia
    Agranulocytosis
    Dizziness
    Weakness
    Elevated liver enzyme levels
    Contraindications
    History of hypersensitivity
    Complete heart block
    Atrial fibrillation or flutter
    Congestive heart failure
    Lupus erythematosus
    Torsade de pointes
    Myasthenia gravis
    Sulfite sensitivity
    Table 22.10 Drug Prototype Table: Procainamide (sources: https://dailymed.nlm.nih.gov/dailymed/; Pritchard & Thompson, 2023)

    Nursing Implications

    The nurse should do the following for clients receiving procainamide intravenously:

    • Place the client on continuous cardiac monitoring.
    • Monitor blood pressure frequently.
    • Monitor level of consciousness.
    • Have other resuscitative equipment and drugs available.
    • Monitor laboratory values, including ANA titer and liver enzyme levels, and report abnormal results to the health care provider
    • Provide client teaching regarding the drug. See below for client teaching guidelines.

    Client Teaching Guidelines

    The client receiving procainamide should:

    • Inform the health care provider of generalized rheumatic pain, dizziness, or weakness.

    In acute ventricular arrhythmias, clients are typically no longer conscious. See Antidysrhythmic Drugs for client teaching guidelines for procainamide in less acute situations.

    FDA Black Box Warning

    Procainamide

    Prolonged administration of procainamide often leads to the development of a positive antinuclear antibody (ANA) test, with or without symptoms of a lupus erythematosus–like syndrome. If a positive ANA titer develops, the benefit versus risks of continued procainamide therapy should be assessed.

    Dopamine and Dobutamine

    After a cardiac event, clients often may still have hypotension or be in shock even after the immediate emergency is over. They may need medications to stabilize their blood pressure so that tissues are perfused. Dopamine and dobutamine are two drugs that help achieve and maintain hemodynamic stability.

    Dopamine

    Endogenous (naturally occurring in the body) dopamine is a hormone that plays a role in stimulating the SNS. Dopamine, an inotropic agent, is converted into epinephrine within the bloodstream. Dopamine binds to alpha-1, alpha-2, beta-1, and dopaminergic receptors. Adrenergic stimulation of alpha-1 and alpha-2 receptors causes vasoconstriction, which leads to increased blood pressure. Adrenergic stimulation of beta-1 receptors directly increases the heart rate.

    Exogenous (synthetic) dopamine mimics the body’s own dopamine to the same effect. Dopamine is used in profound hypotension and shock to increase cardiac output by increasing the rate and force of contraction and blood pressure by vasoconstriction. At low doses (0.5–2 mcg/kg/min), dopamine causes vasodilation and can be used to increase urinary output. At intermediate doses (2–10 mcg/kg/min), it increases heart rate and stroke volume, which leads to increased cardiac output. At high doses, dopamine causes vasoconstriction, which increases blood pressure.

    Adverse Effects and Contraindications

    Dopamine can cause ventricular arrhythmia, atrial fibrillation, ectopic beats, tachycardia, anginal pain, palpitations, cardiac conduction abnormalities, widened QRS complex, bradycardia, hypotension, hypertension, vasoconstriction, dyspnea, azotemia, headache, and anxiety. Extravasation of dopamine into the tissue around an IV site may cause necrosis, sloughing, and potentially gangrene. It is important to note that the benefit of dopamine in a life-threatening event outweighs the risk of adverse effects.

    Contraindications to the use of dopamine include pheochromocytoma, uncorrected tachyarrhythmias or ventricular fibrillation, and allergy to metabisulfite.

    Safety Alert

    Dopamine

    Dopamine may cause peripheral ischemia in clients with a history of occlusive vascular disease.

    Dopamine is a potent drug. It should be administered only in an intensive care area with proper monitoring available.

    Table 22.11 is a drug prototype table for dopamine use in emergency situations. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.

    Drug Class
    Inotrope

    Mechanism of Action
    Converts to epinephrine in the bloodstream, which ultimately causes vasoconstriction and increased rate and force of contraction
    Drug Dosage
    For hemodynamic instability: Initiate titration at 2–5 mcg/kg/min and titrate as directed by health care provider. Titration parameters include blood pressure and signs of tissue perfusion (adequate urine output).
    Indications
    Emergency management of hypotension and shock

    Therapeutic Effects
    Increases heart rate
    Drug Interactions
    Monoamine oxidase inhibitors
    Tricyclic antidepressants
    Beta-adrenergic blockers (may antagonize the effects)
    Alpha-adrenergic blockers (may antagonize the effects)
    Haloperidol
    Cyclopropane or halogenated hydrocarbon anesthetics
    Other vasopressors and oxytocic drugs
    Phenytoin

    Food Interactions
    No significant interactions
    Adverse Effects
    Ventricular arrhythmia
    Atrial fibrillation
    Ectopic beats
    Tachycardia
    Anginal pain
    Palpitations
    Cardiac conduction abnormalities
    Widened QRS complex
    Bradycardia
    Hypotension
    Hypertension
    Vasoconstriction
    Dyspnea
    Azotemia
    Headache
    Anxiety
    Contraindications
    Pheochromocytoma
    Uncorrected tachyarrhythmias or ventricular fibrillation
    Allergy to metabisulfite
    Table 22.11 Drug Prototype Table: Dopamine (sources: https://dailymed.nlm.nih.gov/dailymed/; Sonne et al., 2023)
    Nursing Implications

    The nurse should do the following for clients receiving dopamine intravenously:

    • Place the client on continuous cardiac monitoring.
    • Monitor blood pressure frequently.
    • Monitor level of consciousness.
    • Have resuscitative equipment and drugs available.
    • Monitor IV site for signs of extravasation.
    • Monitor for signs and symptoms of occlusive vascular disease.
    • Provide client teaching regarding the drug. See below for client teaching guidelines.

    Client Teaching Guidelines

    In hypotension or shock, the client may be unconscious.

    If the client receiving dopamine is alert and oriented, the client should:

    • Inform the health care team if they have a change in status (better or worse) after medication administration.
    • Inform the heath care team if they have pain at the IV site.
    • Inform the health care team if they have a headache.

    FDA Black Box Warning

    Dopamine

    Dopamine may cause peripheral ischemia in clients with a history of occlusive vascular disease.

    Dobutamine

    Dobutamine is a beta-1 adrenergic agonist that stimulates the heart to contract more forcefully and, to a lesser extent, faster. It is used for the cardiac decompensation that can occur immediately after a cardiac event.

    Adverse Effects and Contraindications

    Dobutamine can cause increased heart rate, increased blood pressure, ventricular ectopic activity, hypotension, and IV site reaction. It is important to note that the benefit of dobutamine in a life-threatening event outweighs the risk of adverse effects.

    Contraindications to the use of dobutamine include idiopathic hypertrophic subaortic stenosis and hypersensitivity to bisulfite. Use after AMI may be contraindicated because of increased contractility. Dobutamine may cause marked increase in blood pressure or heart rate. Hypovolemia must be corrected prior to initiating dobutamine.

    Clinical Tip

    Dobutamine

    Dobutamine should not be mixed with any other drug in the same solution because it is incompatible with many other drugs.

    Table 22.12 is a drug prototype table for dobutamine. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.

    Drug Class
    Inotrope

    Mechanism of Action
    Directly stimulates beta-1 receptors in the heart, which increases contractility and heart rate
    Drug Dosage
    For hemodynamic instability: Initiate titration at 0.5–1 mcg/kg/min; titrate based on client response, including blood pressure and urine output.
    Indications
    Short-term inotropic support for cardiac decompensation

    Therapeutic Effects
    Increases contractility
    Increases heart rate
    Drug Interactions
    Beta-adrenergic blockers (may reduce the effectiveness of dobutamine)
    Sodium bicarbonate
    Alkaline solutions

    Food Interactions
    No significant interactions
    Adverse Effects
    Increased heart rate
    Increased blood pressure
    Ventricular ectopic activity
    Hypotension
    IV site reaction
    Contraindications
    Idiopathic hypertrophic subaortic stenosis
    Hypersensitivity to bisulfite
    Table 22.12 Drug Prototype Table: Dobutamine (source: https://dailymed.nlm.nih.gov/dailymed/)
    Nursing Implications

    The nurse should do the following for clients receiving dobutamine intravenously:

    • Place the client on continuous cardiac monitoring.
    • Monitor blood pressure frequently.
    • Monitor level of consciousness.
    • Have resuscitative equipment and drugs available.
    • Ensure that dobutamine is not mixed with any other drug in the same solution.
    • Provide client teaching regarding the drug. See below for client teaching guidelines.

    Client Teaching Guidelines

    The client receiving dobutamine should:

    • Inform the health care team if any of these occur:
      • They have a change in status (better or worse) after medication administration.
      • They notice chest pain; dyspnea; or numbness, tingling, or burning in their extremities.
      • They have discomfort or pain at the IV site.

    General Nursing Implications for Cardiac Emergencies and Anaphylaxis

    In the emergency department and critical care unit, nurses are current in cardiopulmonary resuscitation (CPR), advanced cardiac life support (ACLS), advanced trauma life support (ATLS), and other emergency certifications. Many nurses undergo certified emergency nurse (CEN) or certified critical care nurse (CCRN) certification. Advanced training for cardiac and other emergencies is helpful in a fast-paced, stressful environment.

    Case Study

    Read the following clinical scenario to answer the questions that follow.

    James Ryan is a 72-year-old client whose wife brought him to the emergency department because of chest pain and difficulty breathing. He said he was shoveling snow from the sidewalk when he started having pain in his left arm and chest. He also had difficulty catching his breath. After a few minutes, James went inside and sat down, but the pain in his arm and chest continued. He started to feel lightheaded, and even though he was sitting down, he still found it hard to breathe. James wanted to lie down on the couch, but his wife insisted that he go to the emergency department.

    History
    Hypertension

    Current Medications
    Losartan 50 mg daily
    Hydrochlorothiazide 25 mg daily

    Vital Signs Physical Examination
    Temperature: 98.1°F
    • Head, eyes, ears, nose, throat (HEENT): Within defined limits
    • Neurologic: Within defined limits
    • Cardiovascular: No jugular venous distension; S1 and S2 heard on heart auscultation; no S3 noted; brisk capillary refill in nailbeds of hands and feet
    • Respiratory: Clear to auscultation bilaterally
    • GI: Bowel sounds heard in all four quadrants, no tenderness, no distension
    • GU: Appropriate for age
    • Integumentary: Skin appropriate for age
    Blood pressure: 160/92 mm Hg
    Heart rate: 86 beats/min
    Respiratory rate: 20 breaths/min
    Oxygen saturation: 96% on room air
    Height: 5'11"
    Weight: 240 lb
    Table 22.13

    In the emergency department, James underwent an ECG and bloodwork, which revealed he was in the midst of an AMI.

    Exercise \(\PageIndex{1}\)

    The nurse receives orders to administer nitroglycerin sublingually. Which parameter will the nurse monitor to determine the effectiveness of nitroglycerin?

  1. Chest pain
  2. Heart rate
  3. Blood pressure
  4. Level of consciousness
  5. Answer

    Chest pain

    Exercise \(\PageIndex{2}\)

    The health care provider orders aspirin for James. Which action should the nurse take?

  6. Tell James not to chew the aspirin.
  7. Tell James that aspirin will relieve his pain.
  8. Ask James if he has a history of asthma.
  9. Teach James that aspirin causes vasodilation.
  10. Answer

    Ask James if he has a history of asthma.


    This page titled 22.2: Cardiac Emergency Drugs was last modified on Sun, 29 Dec 2024 09:21:30 GMT and is shared under a CC BY 4.0 license and was authored, remixed, and/or curated by OpenStax.